Premium
A multicentre, open, investigator‐initiated phase IV clinical trial to evaluate the efficacy and safety of ingenol mebutate gel, 0·015% on the face and scalp, and 0·05% on the trunk and extremities, in Korean patients with actinic keratosis ( PERFECT )
Author(s) -
Kim Y.C.,
Yang J.Y.,
Yoon J.S.,
Jo S.J.,
Ahn H.H.,
Song K.H.,
Lee D.Y.,
Chung K.Y.,
Won Y.H.,
Kim I.H.
Publication year - 2018
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.16368
Subject(s) - medicine , actinic keratosis , scalp , adverse effect , trunk , dermatology , clinical endpoint , surgery , hyperpigmentation , population , clinical trial , intention to treat analysis , randomized controlled trial , ecology , environmental health , basal cell , biology
Summary Background Ingenol mebutate gel is a novel, field‐directed topical treatment for actinic keratosis ( AK ). Most pivotal studies have targeted Western populations. No clinical study has been conducted to investigate its efficacy and safety in Asian populations. Objectives To evaluate the efficacy and safety of ingenol mebutate gel for treating AK of face/scalp and trunk/extremities in a large Asian (Korean) population. Patients and methods In this multicentre, open‐label, interventional, parallel‐group, prospective phase IV study ( PERFECT , trial registration no.: NCT 02716714), the eligible patients were allocated into either the face/scalp or the trunk/extremities group, according to their selected treatment area location. After application of ingenol mebutate gel, the participants were followed up for 6 months. The primary efficacy endpoint was complete clearance ( CC ) of AK lesions in the selected treatment area at day 57. Quality of life was evaluated using Skindex‐29. Safety endpoints included local skin responses, scar, pigmentation, pain and adverse events. Results In total, 78·1% [95% confidence interval ( CI ) 66·86–86·92%] of subjects had CC at day 57, with 76·6% (95% CI 64·31–86·25%) in the face/scalp group and 88·9% (95% CI 51·75–99·72%) in the trunk/extremities group. Among them, CC was sustained in 88·9% (48 of 54, 95% CI 77·37–95·81%) at month 6. The local skin responses significantly increased 1 day after the treatment compared with baseline, and decreased afterwards. Among the total subjects, 7·8% (6 of 77) had hyperpigmentation on the application area. Scars were not reported. Conclusions Ingenol mebutate is effective for the treatment of AK in Asians, with tolerable safety profiles.